Advertisement Pharmaceutical Business review - Page 415 of 5281 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 10, 2026

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).

Teva will take charge of regulatory submissions and, subject to approval, subsequent commercialisation in the specified territories. Credit: JHVEPhoto / Shutterstock.com.